Indian Bar Association vs WHO | Adv. Dipali Ojha with Rajiv Malhotra

Published September 17, 2021 3,073 Views

Rumble Advocate Dipali Ojha of the Indian bar association and a team of young indian lawyers have issued a legal notice to the world health organization over their blatant campaign against any alternative treatments. Her legal action against WHO comes after the tweet from Soumya Swaminathan, WHO chief scientist, who issued tweet against Iver-mectin backing it with a link, that was declaration from a private company. The team of indian lawyers seeks to make available all possible affordable options to the masses and hold the highest authorities accountable for their directives , and suspected submission to big pharma lobbying.

Timestamp :

00:00 Intro
01:14 Interview Start
02:03 Dipali Ojha background
03:58 Why did Indian Bar association sue WHO ?
11:08 WHO Scientist Twitter statement against treatments
13:04 History of Iver-mectin & Big Pharma profit motive
16:30 Can 8 billion people get vaccine ? options for poor countries
20:19 Dipali Ohja explains indian Protocol & Lawsuit
23:44 Media blackout on Iver-mectin
24:20 role of fact checkers
25:20 AI bias in social media
26:40 Where was the lawsuit filed?
27:10 Dipahli ojha explains cause of 2nd legal notice
32:38 Effects of legal notice
34:50 Many solutions to the crisis
37:14 Diplai ojha explains the Public Interest Litigation
38:52 Rajiv explains the two lawsuits in one
40:54 Challenging Compulsory Vaccine & civil rights
42:28 Role of Gates Foundation , Fauci & Wuhan lab funding
46:50 Dipali Ohja explains WHO's compromised investigations
48:40 Vaccine and complementary treatments
50:24 Role of AI in information bias
51:19 Closing statement of Diplai Ojha

To support Infinity Foundation’s projects including the continuation of such episodes and the research we do:
इनफिनिटी फ़ौंडेशन की परियोजनाओं को अनुदान देने के लिए व इस प्रकार के एपिसोड और हमारे द्वारा किये जाने वाले शोध को जारी रखने के लिए: http://infinityfoundation.com/donate-2/

BREAKING: Rumble to Combine with NASDAQ listed CFVI